Clinical Outcomes of Patients Treated for Candida auris Infections in a Multisite Health System, Illinois, USA

Autor: Joseph Levato, Maya Beganovic, Anthony Chiang, Erik LaChance, Jessica L Miller, Nathan Mai, Jennifer Dela Pena, Kellie Arensman, Morgan Anderson
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Microbiology (medical)
medicine.medical_specialty
Antifungal Agents
Epidemiology
030231 tropical medicine
lcsh:Medicine
Microbial Sensitivity Tests
BSI
susceptibility
lcsh:Infectious and parasitic diseases
CLABSI
03 medical and health sciences
0302 clinical medicine
Antibiotic resistance
Clinical Outcomes of Patients Treated for Candida auris Infections in a Multisite Health System
Illinois
USA
Internal medicine
Amphotericin B
nosocomial infections
medicine
Humans
Candidiasis
Invasive
lcsh:RC109-216
030212 general & internal medicine
antimicrobial resistance
bacteria
Retrospective Studies
business.industry
candidemia
lcsh:R
Micafungin
Outbreak
Candida auris
candidiasis
United States
Infectious Diseases
bacterial infections
Synopsis
Positive culture
Illinois
business
Echinocandins
Fluconazole
medicine.drug
Zdroj: Emerging Infectious Diseases, Vol 26, Iss 5, Pp 876-880 (2020)
Emerging Infectious Diseases
ISSN: 1080-6059
1080-6040
Popis: Candida auris is an emerging fungal pathogen that is typically resistant to fluconazole and is known to cause healthcare-associated outbreaks. We retrospectively reviewed 28 patients who had >1 positive culture for C. auris within a multisite health system in Illinois, USA, during May 2018–April 2019. Twelve of these patients were treated as inpatients for C. auris infections; 10 (83%) met criteria for clinical success, defined as absence of all-cause mortality, C. auris recurrence, and infection-related readmission at 30 days from the first positive culture. The other 2 patients (17%) died within 30 days. Most patients (92%) were empirically treated with micafungin. Four (14%) of 28 total isolates were resistant to fluconazole, 1 (3.6%) was resistant to amphotericin B, and 1 (3.6%) was resistant to echinocandins. Our findings describe low rates of antifungal resistance and favorable clinical outcomes for most C. auris patients.
Databáze: OpenAIRE
Externí odkaz: